A Phase I/II Study of Patient With Newly Diagnosed Primary Central Nervous System Lymphoma Treated With Methotrexate/BBBD, and Adding Rituximab (an Anti CD-20 Antibody) and Carboplatin, to the Treatment Regimen.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Carboplatin (Primary) ; Rituximab (Primary) ; Cytarabine; Folinic acid; Methotrexate; Pegfilgrastim
- Indications CNS cancer; Lymphoma
- Focus Therapeutic Use
- 02 Dec 2020 Biomarkers information updated
- 30 Jul 2013 Planned end date changed from 1 Dec 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov.
- 11 Jan 2012 Planned end date changed from 1 Jun 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.